Could Novavax Win U.S. Authorization for Its COVID Vaccine Sooner Than Expected?

1 min read

Novavax (NASDAQ: NVAX) recently reported very good results from a late-stage study conducted in the United Kingdom of its COVID-19 vaccine candidate. The company’s CEO wants the U.S. Food and Drug Administration (FDA) to consider emergency use authorization for the vaccine based on this U.K. data rather than waiting a few months for results from a U.S. late-stage study. In this Motley Fool Live video recorded on Feb. 3, 2021, contributors Keith Speights and Brian Orelli discuss whether or not Novavax could win U.S. authorization for its COVID vaccine sooner than expected.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Robinhood ETFs: Should You Buy These 5 Top Picks?

Next Story

Here’s What to Like About Tenet Healthcare’s Q4 Results

Latest from Blog